Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by Bradwaiton Feb 27, 2021 10:18am
192 Views
Post# 32678592

Almost 600 Americans Watching AGNPF now on Stocktwits

Almost 600 Americans Watching AGNPF now on StocktwitsSome great comments on the website also.

$AGNPF If this stock in Nasdaq trading, this will be already at 10 bucks. OTC several stock trade above good level. I hope CEO & CFO decides to move this company stock trading to Major index Nasdaq trading soon by Uplift in Nasdaq. Potential after covid19 data announcement - I am waiting for the news

$AGNPF To me, it’s sounds like Algernon Ifenprodil may be a highly effective drug for those who are critically ill with COVID. ...and through the trial they have that it has very positive effects in helping people recover faster and heal! Great news! About, 1 more week until data release. This could be huge!!

$AGNPF “A pill studied at this Miami hospital could help. It’s called Ifenprodil and experts say it shows promise reducing lung inflammation and scarring in critically ill COVID patients. Now the drug’s maker may investigate whether the pill could be used to treat long-haul patients. “There is a potential for us to do additional research to see can it help people who are on their way to recovery but are still struggling and suffering. Can we help with the healing process in their lungs?”Christopher J. Moreau, the CEO of Algernon Pharmaceuticals tells 7 News. whdh.com/news/hank-investig...

 
$AGNPF I know the article I just posted, was posted about an hour ago, but it includes some great info. Not only does it sound like it’s working on the initial goal: “reducing lung inflammation and scarring in critically ill COVID patients.” Additionally, Chris Moreau, the CEO states that there is potential to investigate “potential for us to do additional research to see can it help people who are on their way to recovery but are still struggling and suffering. Can we help with the healing process in their lungs?”.

 

$AGNPF I know the article I just posted, was posted about an hour ago, but it includes some great info. Not only does it sound like it’s working on the initial goal: “reducing lung inflammation and scarring in critically ill COVID patients.” Additionally, Chris Moreau, the CEO states that there is potential to investigate “potential for us to do additional research to see can it help people who are on their way to recovery but are still struggling and suffering. Can we help with the healing process in their lungs?”.


https://stocktwits.com/symbol/AGNPF


<< Previous
Bullboard Posts
Next >>